An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders

Barajaz, Ashley M.; Kliethermes, Christopher L.

doi:10.1016/j.drugalcdep.2017.09.022

Cited by 3 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical data concerning the effectiveness of pharmacological treatments in AUDs is still scarce [107]. Animal studies that evaluate the effect of different AD treatments on preventing alcohol consumption report reduction in alcohol intake after an acute drug dose or under short-term relapse conditions [108].…”

Section: Preclinical Evidence Of Antidepressant Treatment Improves Almentioning

confidence: 99%

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Ballesta¹,

Alén²,

Fonseca³

et al. 2019

Antidepressants - Preclinical, Clinical and Translational Aspects

View full text Add to dashboard Cite

Patients with alcohol use disorders (AUDs) are frequently treated with antidepressant drugs (ADs), but clinical evidence of their efficacy is contradictory. Considering that ADs are thought to produce their therapeutic effects partially by increasing hippocampal plasticity and neurogenesis (HN), and that both AUDs and depression share a potential for the disruption of these neuroplastic processes, one could reasonably wonder whether the poor efficacy of AD treatment could be explained by the inability of these drugs to exert their proper action in patients suffering from AUD or depression. In order to further clarify this question, this chapter aims to examine available data regarding the effect of ADs on behavioral and HN alterations related to alcohol abstinence, as a key period in which the treatment would be implemented and in which their potential effects on alcohol-related problems remain under controversy.

show abstract

Section: Preclinical Evidence Of Antidepressant Treatment Improves Almentioning

confidence: 99%

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Ballesta¹,

Alén²,

Fonseca³

et al. 2019

Antidepressants - Preclinical, Clinical and Translational Aspects

View full text Add to dashboard Cite

show abstract

“…Integration across the highly diverse subfields of alcohol research in nonhuman subjects is needed to maximize the insight and advances gained [14,15]. Indeed, retrospective evaluations of animal disease models indicate the utility of frameworks which explicitly create avenues for researchers to synthesize findings and provide continuity across subfields [16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Structured tracking of alcohol reinforcement (STAR) for basic and translational alcohol research

et al. 2023

View full text Add to dashboard Cite

There is inherent tension between methodologies developed to address basic research questions in model species and those intended for preclinical to clinical translation: basic investigations require flexibility of experimental design as hypotheses are rapidly tested and revised, whereas preclinical models emphasize standardized protocols and specific outcome measures. This dichotomy is particularly relevant in alcohol research, which spans a diverse range of basic sciences in addition to intensive efforts towards understanding the pathophysiology of alcohol use disorder (AUD). To advance these goals there is a great need for approaches that facilitate synergy across basic and translational areas of nonhuman alcohol research. In male and female mice, we establish a modular alcohol reinforcement paradigm: Structured Tracking of Alcohol Reinforcement (STAR). STAR provides a robust platform for quantitative assessment of AUD-relevant behavioral domains within a flexible framework that allows direct crosstalk between translational and mechanistically oriented studies. To achieve cross-study integration, despite disparate task parameters, a straightforward multivariate phenotyping analysis is used to classify subjects based on propensity for heightened alcohol consumption and insensitivity to punishment. Combining STAR with extant preclinical alcohol models, we delineate longitudinal phenotype dynamics and reveal putative neuro-biomarkers of heightened alcohol use vulnerability via neurochemical profiling of cortical and brainstem tissues. Together, STAR allows quantification of time-resolved biobehavioral processes essential for basic research questions simultaneous with longitudinal phenotyping of clinically relevant outcomes, thereby providing a framework to facilitate cohesion and translation in alcohol research.

show abstract

Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders

Lawrence

2018

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders

Cited by 3 publications

References 93 publications

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis

Structured tracking of alcohol reinforcement (STAR) for basic and translational alcohol research

Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders

Contact Info

Product

Resources

About